SCHEMBL2991276

SCHEMBL2991276

COc1ccc2c(c1)c(C(=O)C(=O)NC1CCCCC1)c(C)n2Cc1ccc(Cl)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.57
TSHR P16473 3/20 0.57
LMNA P02545 2/20 0.57
CYP1A2 P05177 2/20 0.57
CYP3A4 P08684 2/20 0.57
CYP2C9 P11712 2/20 0.57
CYP2C19 P33261 2/20 0.57
PMP22 Q01453 2/20 0.57
MEN1 O00255 1/20 0.57
RGS12 O14924 1/20 0.57
MAPT P10636 1/20 0.57
PKM P14618 1/20 0.57
NFKB1 P19838 1/20 0.57
MAPK1 P28482 1/20 0.57
GNAI1 P63096 1/20 0.57
KMT2A Q03164 1/20 0.57
HIF1A Q16665 1/20 0.57
PLA2G2A P14555 5/20 0.56
FAAH O00519 1/20 0.52
PTGS2 P35354 4/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4083920 0.95 ALDH1A1 (0.60) ALDH1A1TSHRLMNACYP1A2CYP3A4
SCHEMBL3001965 0.92 MAPT (0.51) ALDH1A1TSHRLMNACYP1A2CYP3A4
SCHEMBL3008192 0.91 ALDH1A1 (0.52) ALDH1A1TSHRLMNACYP1A2CYP3A4
SCHEMBL4083893 0.91 CNR2 (0.50) ALDH1A1TSHRLMNACYP1A2CYP3A4
SCHEMBL4388976 0.89 ALDH1A1 (0.50) ALDH1A1TSHRLMNACYP1A2CYP3A4
SCHEMBL3004246 0.89 ALDH1A1 (0.52) ALDH1A1TSHRLMNACYP1A2CYP3A4
SCHEMBL2992971 0.89 FAAH (0.57) MEN1MAPTKMT2AFAAHCNR2
SCHEMBL4094141 0.89 MAPT (0.48) ALDH1A1TSHRLMNACYP1A2CYP3A4
SCHEMBL3006378 0.88 PLA2G2A (0.49) ALDH1A1TSHRLMNACYP1A2CYP3A4
SCHEMBL4382618 0.87 PLA2G2A (0.49) ALDH1A1TSHRLMNACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118503-A1 FAAH INHIBITORS IRONWOOD PHARMACEUTICALS, INC. 2009-05-07 US claimed
US-8884020-B2 Indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2014-11-11 US disclosed
EP-2610244-A1 Indole compounds Ironwood Pharmaceuticals, Inc. (US) 2013-07-03 EP disclosed
US-20100197708-A1 INDOLE COMPOUNDS WELLS FARGO BANK, NATIONAL ASSOCIATION 2010-08-05 US disclosed
EP-2049520-A2 INDOLE COMPOUNDS Ironwood Pharmaceuticals, Inc. (US) 2009-04-22 EP disclosed
WO-2008019357-A2 INDOLE COMPOUNDS IRONWOOD PHARMACEUTICALS, INC. (US) 2008-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197708-A1 INDOLE COMPOUNDS IDO1, IDO2, TPH2 ALDH1A1 1229/4885TSHR 3577/4885LMNA 3450/4885
US-20090118503-A1 FAAH INHIBITORS FAAH, FAAH2, CNR2 ALDH1A1 648/4885TSHR 3365/4885LMNA 4089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.